Inuvair is developed by Wilfried De Backer.

What development phase is Inuvair in?

Inuvair is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

Inuvair

Wilfried De Backer · FDA-approved active Small molecule Quality 0/100

At a glance

Generic name	Inuvair
Sponsor	Wilfried De Backer
Modality	Small molecule
Therapeutic area	Other
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Evaluate the Effects of Formoterol and Beclomethasone Dipropionate Combination Therapy on Small Airways Function (PHASE4)
Study to Assess the Effect of Formoterol and Beclomethasone Dipropionate in Asthmatic Patients (PHASE4)
Study to Assess the Effect of Formoterol and Beclomethasone Dipropionate in Patients With Chronic Obstructive Pulmonary Disease (COPD) (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Inuvair CI brief — competitive landscape report
Inuvair updates RSS · CI watch RSS
Wilfried De Backer portfolio CI